PMID- 36758973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240207
IS  - 2287-1012 (Print)
IS  - 2287-1292 (Electronic)
IS  - 2287-1012 (Linking)
VI  - 28
IP  - 4
DP  - 2023 Dec
TI  - Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and 
      obesity in Korea: a pilot study.
PG  - 296-301
LID - 10.6065/apem.2244196.098 [doi]
AB  - PURPOSE: We sought to investigate the effects and side effects of once-weekly 
      dulaglutide treatment for type 2 diabetes mellitus (T2DM) in patients <18 years 
      of age in Korea. METHODS: : From the Eulji University Hospital database, we 
      identified all patients <18 years of age diagnosed with T2DM and treated with 
      dulaglutide from January 1, 2017, to July 31, 2022. RESULTS: We identified 5 
      patients <18 years of age treated with dulaglutide for T2DM management. Their 
      mean (standard deviation [SD]) age was 16.6 (0.5) years. Four (80%) patients were 
      female. The mean (SD) body mass index was 29.4 (5.1) kg/m2, and the mean (SD) age 
      at diagnosis was 15.2 (1.6) years. Four patients had been treated previously with 
      metformin alone or in combination with insulin. Four patients were treated with 
      1.5 mg of dulaglutide and one was treated with 0.75 mg of dulaglutide. The mean 
      (SD) hemoglobin A1c concentrations at baseline, 3 months after treatment, and 1 
      year after treatment, respectively, were 10.0% (2.2%), 6.5% (1.5%), and 6.7% 
      (1.4%), with significant differences. In addition, at baseline, 3 months after 
      treatment, and 1 year after treatment, the mean (SD) body weight values were 79.7 
      (13.3) kg, 80.2 (14.0) kg, and 81.1 (15.3) kg, with no significant difference. 
      CONCLUSION: Use of once-weekly dulaglutide for juvenile T2DM ensures very good 
      glycemic control, with few side effects and good adherence, indicating its 
      potential as a promising therapeutic agent in this age group. Nationwide studies 
      are warranted to confirm our results.
FAU - Seo, Ji Young
AU  - Seo JY
AD  - Department of Pediatrics, Nowon Eulji University Hospital, Eulji University 
      School of Medicine, Seoul, Korea.
FAU - Lee, Cha Gon
AU  - Lee CG
AD  - Department of Pediatrics, Nowon Eulji University Hospital, Eulji University 
      School of Medicine, Seoul, Korea.
FAU - Choi, Hoonsung
AU  - Choi H
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Korea.
FAU - Lee, Hong Kyu
AU  - Lee HK
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul 
      National University College of Medicine, Seoul, Korea.
FAU - Lee, So Young
AU  - Lee SY
AD  - Department of Internal Medicine, Nowon Eulji University Hospital, Eulji 
      University School of Medicine, Seoul, Korea.
FAU - Kim, Hyo-Jeong
AU  - Kim HJ
AD  - Department of Internal Medicine, Nowon Eulji University Hospital, Eulji 
      University School of Medicine, Seoul, Korea.
FAU - Jung, Kyong Yeun
AU  - Jung KY
AD  - Department of Internal Medicine, Nowon Eulji University Hospital, Eulji 
      University School of Medicine, Seoul, Korea.
FAU - Kim, Jin Taek
AU  - Kim JT
AD  - Department of Internal Medicine, Nowon Eulji University Hospital, Eulji 
      University School of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20230203
PL  - Korea (South)
TA  - Ann Pediatr Endocrinol Metab
JT  - Annals of pediatric endocrinology & metabolism
JID - 101588279
CIN - Ann Pediatr Endocrinol Metab. 2023 Dec;28(4):235-236. PMID: 38173379
PMC - PMC10765027
OTO - NOTNLM
OT  - Adolescent
OT  - Dulaglutide
OT  - Obesity
OT  - Type 2 diabetes mellitus
COIS- Conflicts of interest No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2023/02/10 06:00
MHDA- 2023/02/10 06:01
PMCR- 2023/12/01
CRDT- 2023/02/09 20:24
PHST- 2022/08/23 00:00 [received]
PHST- 2022/10/05 00:00 [accepted]
PHST- 2023/02/10 06:01 [medline]
PHST- 2023/02/10 06:00 [pubmed]
PHST- 2023/02/09 20:24 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - apem.2244196.098 [pii]
AID - apem-2244196-098 [pii]
AID - 10.6065/apem.2244196.098 [doi]
PST - ppublish
SO  - Ann Pediatr Endocrinol Metab. 2023 Dec;28(4):296-301. doi: 
      10.6065/apem.2244196.098. Epub 2023 Feb 3.